THRX Projected Dividend Yield

Theseus Pharmaceuticals Inc ( NASDAQ : THRX )

Theseus Pharmaceuticals is engaged in the discovery, development and commercialization of targeted therapies for cancer patients. Co.'s development programs are designed to address drug resistance mutations in key driver oncogenes. Co.'s product candidate, THE-630, is a pan-variant inhibitor of all main classes of activating and resistance mutations of the KIT kinase for the treatment of gastrointestinal stromal tumours. Co.'s second program is focused on inhibitors of epidermal growth factor receptor (EGFR), that are active against C797S, the common EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer.

20 YEAR PERFORMANCE RESULTS